Calcium oxalate crystal deposition in metabolic syndrome model rat kidneys

International Journal of Urology

Volumn 17, Issue 12, 2010, Pages 996-1003

  Okamoto, Masanori ^a   Kohjimoto, Yasuo ^b   Iba, Akinori ^b   Saji, Fumie ^a   Hara, Isao ^b   Shigematsu, Takashi ^a  

^a Division of Nephrology   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Metabolic syndrome; Nephrolithiasis; Obesity; Otsuka Long Evans Tokushima fatty rat

Indexed keywords

CALCIUM OXALATE; DRINKING WATER; ETHYLENE GLYCOL; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CALCIUM URINE LEVEL; CONTROLLED STUDY; CRYSTAL; HISTOPATHOLOGY; HYPEROXALURIA; KIDNEY; MALE; METABOLIC SYNDROME X; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; RECEPTOR UPREGULATION; URIC ACID URINE LEVEL; URINALYSIS; URINARY EXCRETION; URINE ACIDIFICATION;

ANIMALS; BODY WEIGHT; CALCIUM OXALATE; CHEMOKINE CCL2; CRYSTALLIZATION; DISEASE MODELS, ANIMAL; HYPEROXALURIA; KIDNEY; MALE; METABOLIC SYNDROME X; NEPHROLITHIASIS; OSTEOPONTIN; RATS; RATS, INBRED OLETF; RATS, LONG-EVANS; URINE;

EID: 78649626751     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02661.x     Document Type: Article

References (36)

1. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005; 68: 1230-5.
2. Madore F, Stampfer MJ, Rimm EB, Curhan GC. Nephrolithiasis and risk of hypertension. Am. J. Hypertens. 1998; 11: 46-53.
3. Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: a review. Am. J. Hypertens. 2008; 21: 257-64.
4. Eckel RH, Grundy SM, Zimmert PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
5. West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the national health and nutrition examination survey (NHANES III) 1998-1994. Am. J. Kidney Dis. 2008; 51: 741-7.
6. Siener R, Glatz S, Nicolay C, Hesse A. The role of overweight and obesity in calcium oxalate stone formation. Obes Res. 2004; 12: 106-13.
7. Iba A, Kohjimoto Y, Mori T et al. Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome. BJU Int. 2010; 106: 1550-4.
8. Kahn SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin. Exp. Nephrol. 2004; 8: 75-88.
9. Tilg H, Moschen AR. Inflammatory mechanism in the regulation of insulin resistance. Mol. Med. 2008; 14: 222-31.
10. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications; Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41: 1422-8.
11. Pickavance LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JPH. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br. J. Pharmacol. 1999; 128: 1570-6.
12. Toblli JE, Ferder L, Stella I, De Cavanaugh EM, Angerosa M, Inserra F. Effects of angiotensin II subtype 1 receptor blockade by losartan tubulointerstitial lesions caused by hyperoxaluria. J. Urol. 2002; 168: 1550-5.
13. Khan SR. Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. Scanning Microsc. 1995; 9: 89-100.
14. Kahn SR. Animal model of calcium oxalate nephrolithiasis. In: Kahn SR (ed.). Calcium Oxalate in Biological Systems. CRC Press, Inc., New York, 1995; 343-59.
15. Poldelski V, Johnson A, Wright S, Rosa VD, Zager RA. Ethylene-glycol-mediated tubular injury: identification of critical metabolites and injury pathways. Am. J. Kidney Dis. 2001; 38: 339-48.
16. Gelber RP, Kurth T, Kausz AT et al. Association between body mass index and CKD in apparently healthy men. Am. J. Kidney Dis. 2005; 46: 871-80.
17. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk for chronic renal failure. J. Am. Soc. Nephrol. 2006; 17: 1695-702.
18. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004; 65: 1422-5.
19. Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J. Am. Soc. Nephrol. 2006; 17: 2026-33.
20. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004; 65: 386-92.
21. Coe FL, Kavalach AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N. Engl. J. Med. 1974; 291: 1344-50.
22. Coe FL, Strauss AL, Tembe V, Le Dun S. Uric acid saturation in calcium nephrolithiasis. Kidney Int. 1980; 17: 662-8.
23. Hudkins KL, Giachelli CM, Cui Y, Couser WG, Johnson RJ, Alpers CE. Osteopontin expression in fetal and mature human kidney. J. Am. Soc. Nephrol. 1999; 10: 444-57.
24. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 2001; 60: 1645-57.
25. Kahn SR, Johnson JM, Peck AB, Cornelius JM, Glenton PA. Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J. Urol. 2002; 168: 1173-81.
26. Kelly DJ, Wilkinson-Berka JL, Ricardo SD, Cox AJ, Gilbert RE. Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic(mRen-2)27 rats. Nephrol. Dial. Transplant. 2002; 17: 985-91.
27. Wesson JA, Johnson RJ, Mazzali M et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J. Am. Soc. Nephrol. 2003; 14: 139-47.
28. Konya E, Umekawa T, Iguchi M, Kurita T. The role of osteopontin on calcium oxalate crystal formation. Eur. Urol. 2003; 43: 564-71.
29. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 1998; 152: 353-8.
30. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin. Exp. Nephrol. 2004; 8: 75-88.
31. Matlaga BR, Coe FL, Evan AP, Lingeman JE. The role of Randall's plaques in the pathogenesis of calcium stones. J. Urol. 2007; 177: 31-8.
32. Sepe V, Adamo G, La Fianza A et al. Henle loop basement membrane as initial site for Randall plaque formation. Am. J. Kidney Dis. 2006; 48: 706-11.
33. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 2003; 100: 7265-70.
34. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006; 69: 73-80.
35. Ando K, Fujita T. Metabolic syndrome and oxidative stress. Free Radic. Biol. Med. 2009; 47: 213-18.
36. Umekawa T, Tsuji H, Uemura H, Khan SR. Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int. 2009; 104: 115-20.